Schering-Plough Adds Levitra To Product Portfolio Through Deal With Bayer
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer abandons primary care market in U.S. and will cut 1,800 sales positions. Schering-Plough will take over marketing of Avelox and Cipro as well as Bayer's portion of Levitra co-promotion efforts.
You may also be interested in...
DTC Advertising "Tone-Down" Could Address FDA Concerns, Schering Says
Marketers will begin airing more balanced DTC ads as a result of increased scrutiny from FDA about the quality of some ads, Schering CFO Bertolini says. With Levitra, Schering now participates in what may be a high-risk market for DTC ads: erectile dysfunction disorder.
DTC Advertising "Tone-Down" Could Address FDA Concerns, Schering Says
Marketers will begin airing more balanced DTC ads as a result of increased scrutiny from FDA about the quality of some ads, Schering CFO Bertolini says. With Levitra, Schering now participates in what may be a high-risk market for DTC ads: erectile dysfunction disorder.
Phase III Antibiotic Garenoxacin Will Be Out-Licensed, Schering Says
Schering-Plough will out-license U.S. rights to the Phase III quinolone antibiotic garenoxacin due to potential conflicts of interest related to the company's primary care marketing agreement with Bayer